• KOL
    • KOLs Community
    • Ovarian
    • Ovarian Cancer
    • Eric Pujade‐lauraine
    • Eric Pujade‐Lauraine

      Eric Pujade‐Lauraine

      ARCAGY-GINECO, and GINECO, Paris, France; | Groupe ARCAGY-GINECO, Pôle opérations cliniques, Paris, France | ARCAGY Research, and GINECO, Paris, France; | ARCAGY-GINECO ...



      KOL Resume for Eric Pujade‐Lauraine


      ARCAGY-GINECO, and GINECO, Paris, France;

      ARCAGY-GINECO Université Paris Descartes, AP-HP, Paris, France.

      Université Paris Descartes, Paris, France


      University Paris Descartes, ARCAGY-GINECO, France

      Arcagy-Gineco, Paris, USA


      Association de Recherche sur les Cancers dont Gynécologiques–GINECO, Université Paris Descartes, Assistance Publique–Hôpitaux de Paris, Paris, France


      Assistance Publique - Hopitaux De Paris, GINECO Group, Paris, France


      ARCAGY Research, Paris and Gineco, Paris


      GINECO & Universite Paris Descartes, Paris, France;

      Medical Oncology Department, Universite Paris Descartes, AH-HP, Paris, France


      Cancer de la femme et recherche clinique, Groupe hospitalier Hôtel Dieu (AP-HP), Paris, France


      GINECO, Université Paris Descartes, AP-HP, Paris, France

      Université Paris Descartes, APHP, Hôpital Hôtel-Dieu, Paris


      Centre des cancers de la femme et recherche clinique, GH Paris Centre, site Hôtel-Dieu, 1 place du Parvis Notre-Dame, 75181, Paris cedex 04, France

      European Network of Gynaecological Oncological Trial Groups, Geneva, Switzerland.



      Eric Pujade‐Lauraine: Influence Statistics

      Sample of concepts for which Eric Pujade‐Lauraine is among the top experts in the world.
      Concept World rank
      pau complex #1
      ca125 kinetics chemotherapy #1
      bevacizumab singleagent chemotherapy #1
      epi tax #1
      cell migration igrov1 #1
      irc assessment pfs #1
      chemotherapy roc patients #1
      glandular pfi #1
      1 ewot1 #1
      efficacy continuous lenalidomide #1
      bévacizumab therapy #1
      pulmonary function bleomycin #1
      ca125 recist #1
      eortc criteria correlation #1
      tomao #1
      glycols topotecan #1
      behalf gineco #1
      ov1 tyrosine #1
      gineco phase study #1
      iii solo2 #1
      535 roc patients #1
      nice saintpauldevence #1
      ewot2 #1
      stage ovarian malignancy #1
      ovarian cnacer patients #1
      ewot1 #1
      platinumresistant #1
      cancer gineco #1
      patients egfr1 #1
      ovarian cancer—reply #1
      ovárico #1
      gineco study #1
      olaparib aes #1
      eortc matv #1
      french groupe #1
      figo pai2 #1
      roc 6 months #1
      concurrent bev #1
      cartaxhy #1
      scst treatment #1
      matv tlg survival #1
      tax regimen #1
      phase iiib efficacy #1
      analysis age subgroups #1
      optimal initial surgery #1
      bevacizumab 15 months #1
      parental igrov1 cell #1
      resistant aoc #1
      percist criteria patients #1
      gineco #1


      Prominent publications by Eric Pujade‐Lauraine

      KOL-Index: 24891

      BACKGROUND: The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression. We report the final overall survival results of the trial.

      METHODS: ICON7 was an international, phase 3, open-label, randomised trial undertaken at 263 centres in 11 countries across Europe, Canada, Australia and New Zealand. Eligible adult women ...

      Known for Standard Chemotherapy | Ovarian Cancer | Bevacizumab Women | Difference Survival | Months 95
      KOL-Index: 24569

      BACKGROUND: Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients with platinum-sensitive, relapsed high-grade serous ovarian cancer. We aimed to confirm these findings in patients with a BRCA1 or BRCA2 (BRCA1/2) mutation using a tablet formulation of olaparib.

      METHODS: This international, multicentre, double-blind, randomised, placebo-controlled, phase 3 trial evaluated olaparib ...

      Known for Patients Olaparib | 3 Trial | Relapsed Ovarian | Brca1 Genes | Maintenance Therapy
      KOL-Index: 19308

      BACKGROUND: In the Gynecologic Cancer Intergroup International Collaboration on Ovarian Neoplasms 7 (ICON7) trial, bevacizumab improved progression-free survival in patients with ovarian cancer when used in combination with first-line chemotherapy and as a single-drug continuation treatment for 18 cycles. In a preliminary analysis of a high-risk subset of patients, there was also an improvement in overall survival. This study aims to describe the health-related quality-of-life (QoL) ...

      Known for Standard Chemotherapy | Ovarian Cancer | Randomised Trial | Women Bevacizumab | International Collaboration
      KOL-Index: 18297

      BACKGROUND: Carboplatin plus paclitaxel administered every 3 weeks is standard first-line chemotherapy for patients with advanced ovarian cancer. A weekly paclitaxel schedule combined with carboplatin every 3 weeks prolonged progression-free survival and overall survival in a Japanese phase 3 trial. The aim of our study was to assess whether a weekly schedule of carboplatin plus paclitaxel is more effective than the same drugs given every 3 weeks.

      METHODS: We did a multicentre, ...

      Known for 3 Weeks | Advanced Ovarian Cancer | Carboplatin Paclitaxel | Weekly Schedule | Chemotherapy Women
      KOL-Index: 18072

      PURPOSE: Cross-talk between signal transduction pathways likely contributes to hormone resistance in metastatic breast cancer (mBC). Everolimus, an oral inhibitor of the mammalian target of rapamycin, has restored sensitivity in endocrine-resistance models and shown anticancer activity in early-phase mBC clinical trials. This analysis evaluated efficacy and safety of everolimus in combination with tamoxifen in patients with mBC resistant to aromatase inhibitors (AIs).

      PATIENTS AND ...

      Known for Hormone Receptor | Tamoxifen Everolimus | Prior Exposure | Patients Mbc | Metastatic Breast
      KOL-Index: 16125

      BACKGROUND: In the phase 3 SOLO2 trial (ENGOT Ov-21), maintenance therapy with olaparib tablets significantly prolonged progression-free survival (primary endpoint) compared with placebo in patients with a germline BRCA1 or BRCA2 (BRCA1/2) mutation and platinum-sensitive, relapsed ovarian cancer who had received two or more lines of previous chemotherapy. The most common subjective adverse effects included fatigue, nausea, and vomiting, which were typically low grade and self-limiting. ...

      Known for Olaparib Placebo | Life Hrqol | Phase 3 | Primary Endpoint | Centred Outcomes
      KOL-Index: 15722

      BACKGROUND: The combination of carboplatin and paclitaxel is the standard of care for the treatment of ovarian cancer, yet rates of recurrence and death remain high. We performed a prospective randomized phase III study to examine whether sequential administration of topotecan can improve the efficacy of carboplatin and paclitaxel in first-line treatment of advanced epithelial ovarian cancer.

      METHODS: A total of 1308 patients with previously untreated ovarian cancer (International ...

      Known for Ovarian Cancer | Carboplatin Paclitaxel | Patients Arm | Phase Iii | Firstline Treatment
      KOL-Index: 15473

      PURPOSE: In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard. Bevacizumab is active alone and in combination. AURELIA is the first randomized phase III trial to our knowledge combining bevacizumab with chemotherapy in platinum-resistant OC.

      PATIENTS AND METHODS: Eligible patients had measurable/assessable OC that had progressed < 6 months after completing platinum-based therapy. Patients with refractory disease, history of bowel obstruction, or > two prior ...

      Known for Bevacizumab Chemotherapy | Phase Iii | Antibodies Monoclonal | Humanized Antineoplastic | Pfs Orr
      KOL-Index: 15213

      PURPOSE: The objective of this study was to compare the efficacy and safety of trabectedin plus pegylated liposomal doxorubicin (PLD) with that of PLD alone in women with recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy.

      PATIENTS AND METHODS: Women > or = 18 years, stratified by performance status (0 to 1 v 2) and platinum sensitivity, were randomly assigned to receive an intravenous infusion of PLD 30 mg/m(2) followed by a 3-hour infusion of trabectedin ...

      Known for Recurrent Ovarian Cancer | Trabectedin Pld | Pfs Orr | Liposomal Doxorubicin | Hazard Ratio
      KOL-Index: 14940

      BACKGROUND: Most patients with ovarian cancer will relapse after receiving frontline platinum-based chemotherapy and eventually develop platinum-resistant or platinum-refractory disease. We report results of avelumab alone or avelumab plus pegylated liposomal doxorubicin (PLD) compared with PLD alone in patients with platinum-resistant or platinum-refractory ovarian cancer.

      METHODS: JAVELIN Ovarian 200 was an open-label, parallel-group, three-arm, randomised, phase 3 trial, done at 149 ...

      Known for Ovarian Cancer | Avelumab Combination | Immune Checkpoint Inhibitors | Patients Platinum | Phase 3
      KOL-Index: 13574

      PURPOSE: This randomized, noncomparative, parallel-group study was designed to evaluate the pathologic complete response (pCR) rate of combined doxorubicin plus paclitaxel (AP) and doxorubicin plus cyclophosphamide (AC) as neoadjuvant chemotherapy in patients with previously untreated breast cancer who were unsuitable for conservative surgery.

      PATIENTS AND METHODS: A total of 200 patients with T2-3, N0-1, M0 disease were randomly assigned in a 2:1 ratio to receive preoperative ...

      Known for Neoadjuvant Treatment | Breast Cancer | Doxorubicin Paclitaxel | Patients Pcr | Preoperative Chemotherapy
      KOL-Index: 12502

      AIM: Trabectedin in combination with pegylated liposomal doxorubicin (PLD) improves progression-free survival (PFS) compared to PLD alone in recurrent ovarian cancer (J Clin Oncol 2010;28:3107-14).

      METHODS: Women, stratified by performance status (0-1 versus 2) and platinum sensitivity (platinum-free interval [PFI]<6 versus ≥ 6 months), were randomly assigned to receive PLD 30 mg/m(2) IV followed by a 3-h infusion of trabectedin 1.1mg/m(2) every 3 weeks or PLD 50mg/m(2) every 4 weeks. ...

      Known for Pegylated Liposomal Doxorubicin | Local Neoplasms | Trabectedin Pld | Platinum Sensitivity | Polyethylene Glycols
      KOL-Index: 12441

      PURPOSE: This randomized, multicenter, phase III noninferiority trial was designed to test the efficacy and safety of the combination of pegylated liposomal doxorubicin (PLD) with carboplatin (CD) compared with standard carboplatin and paclitaxel (CP) in patients with platinum-sensitive relapsed/recurrent ovarian cancer (ROC).

      PATIENTS AND METHODS: Patients with histologically proven ovarian cancer with recurrence more than 6 months after first- or second-line platinum and taxane-based ...

      Known for Carboplatin Paclitaxel | Pegylated Liposomal Doxorubicin | Ovarian Cancer | Patients Platinum | 3 Weeks
      KOL-Index: 12311

      Purpose Seribantumab is a fully human immunoglobulin G2 monoclonal antibody that binds to human epidermal growth factor receptor (HER) 3 (ErbB3), blocking heregulin (HRG) -mediated ErbB3 signaling and inducing ErbB3 receptor downregulation. This open-label randomized phase II study evaluated progression-free survival (PFS) with seribantumab in combination with once-per-week paclitaxel compared with paclitaxel alone in patients with platinum-resistant or -refractory ovarian cancer. A key ...

      Known for Monoclonal Antibodies | Ovarian Cancer | Seribantumab Combination | 95 Patients | Randomized Phase

      Key People For Ovarian Cancer

      Top KOLs in the world
      Ahmedin M Jemal
      united states breast cancer addis ababa
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      Ignace B P Vergote
      ovarian cancer neoadjuvant chemotherapy advisory consultancy
      Robert C Bast
      ovarian cancer early detection bone marrow
      Beth Young Karlan
      ovarian cancer brca2 mutation brca1 genes
      Anil K Sood
      ovarian cancer tumor growth gene expression

      Eric Pujade‐Lauraine:Expert Impact

      Concepts for whichEric Pujade‐Laurainehas direct influence:Ovarian cancer,  Advanced ovarian cancer,  Maintenance olaparib,  Phase iii,  Standard chemotherapy,  Pegylated liposomal doxorubicin,  Maintenance therapy.

      Eric Pujade‐Lauraine:KOL impact

      Concepts related to the work of other authors for whichfor which Eric Pujade‐Lauraine has influence:Ovarian cancer,  Parp inhibitors,  Neoadjuvant chemotherapy,  Maintenance therapy,  Fallopian tube,  Pegylated liposomal doxorubicin,  Cytoreductive surgery.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      ARCAGY-GINECO, and GINECO, Paris, France; | Groupe ARCAGY-GINECO, Pôle opérations cliniques, Paris, France | ARCAGY Research, and GINECO, Paris, France; | ARCAGY-GINECO Université Paris Descartes, AP-HP, Paris, France. | Université Paris Descartes, P

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.